MAP2K7 and ameloblastoma: Reported attempts to treat ameloblastomas with BRAF inhibitors (BRAFi) [with/without mitogen-activated protein kinase (MEK) inhibitors (MEKi)] as a last line treatment, have been successful for seven patients with recurrent inoperable conventional ameloblastomas, even some with lung metastatic deposits [7–14].